Equities
  • Price (CHF)557.08
  • Today's Change0.000 / 0.00%
  • Shares traded15.50k
  • 1 Year change+61.38%
  • Beta--
Data delayed at least 20 minutes, as of Nov 14 2024 17:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

  • Revenue in CHF (TTM)6.70bn
  • Net income in CHF573.00m
  • Incorporated2002
  • Employees17.83k
  • Location
    Lonza Group AGMuenchensteinerstrasse 38BASEL 4002SwitzerlandCHE
  • Phone+41 613168111
  • Fax+41 613169111
  • Websitehttps://www.lonza.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LONN:SWX since
announced
Transaction
value
Genentech Inc-Biologics Manufacturing Facility,Vacaville,CaliforniaDeal completed20 Mar 202420 Mar 2024Deal completed15.89%1.20bn
Data delayed at least 15 minutes, as of Nov 14 2024 16:34 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.